卵巢癌居妇科肿瘤死亡原因之首,因其起病隐匿,缺乏敏感的早期诊断工具,约70％的患者就诊时已属进展期,并且约60％～70％的患者5年内复发或死亡.因此,提高患者生存率的关键是早期诊断和早期治疗.肿瘤标志物在恶性肿瘤的早期诊断、病情监测及疗效评价中有重要价值.近年来,许多学者对检测新型肿瘤标志物糖类抗原125(CA125)、人附睾分泌蛋白4(HE4)和卵巢恶性肿瘤发病风险模型(ROMA)在卵巢癌中的应用做了大量研究.本文对CA125、HE4联合检测及ROMA模型在卵巢癌诊断、鉴别诊断及预后判断中的研究进展作一综述.%Ovarian cancer is the leading cause of death among gynecologic malignancies.Due to the hidden onset and the lack of diagnostic tools for early detection,about 70％ of patients are detected at a progressed stage of disease,while 60％-70％ of patients with ovarian cancer relapse or die within 5 years after diagnosis.The key to improve survival is early diagnosis and early treatment.Tumor markers have significant values in early diagnosis,monitoring and therapeutic evaluation of malignant tumors.Many researchers have done tons of researches on novel tumor markers human epididymis secretory protein 4(HE4),carbohydrate antigen 125(CA125)and risk of ovarian malignancy algorithm in the diagnosis,differential diagnosis and prognosis of ovarian cancer recently.The present article is a review of those studies.
展开▼
